KBC Group NV Increases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

KBC Group NV raised its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 2,275.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,010 shares of the biopharmaceutical company’s stock after buying an additional 58,442 shares during the period. KBC Group NV owned about 0.07% of Ultragenyx Pharmaceutical worth $2,567,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of RARE. Algert Global LLC increased its position in shares of Ultragenyx Pharmaceutical by 46.9% in the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock valued at $4,105,000 after acquiring an additional 23,580 shares during the period. Bamco Inc. NY purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $2,666,000. Principal Financial Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 740.0% in the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after buying an additional 76,150 shares in the last quarter. Cerity Partners LLC purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $1,773,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 294 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the subject of a number of recent analyst reports. Wedbush restated a “neutral” rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. TD Cowen lifted their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wells Fargo & Company lifted their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. JPMorgan Chase & Co. cut their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $92.43.

Ultragenyx Pharmaceutical Trading Down 0.9 %

Ultragenyx Pharmaceutical stock opened at $43.03 on Friday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The company has a market cap of $3.97 billion, a PE ratio of -6.65 and a beta of 0.58. The company’s 50-day moving average is $44.29 and its two-hundred day moving average is $49.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 42.3% on a year-over-year basis. During the same period last year, the company posted ($2.23) EPS. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.13 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 8,273 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the transaction, the chief executive officer now owns 2,195,712 shares in the company, valued at approximately $109,785,600. This represents a 0.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.80% of the stock is owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.